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A Corrigendum on
The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis
by Magcwebeba, T., Dorhoi, A., and du Plessis, N. (2019). Front. Immunol. 10:917.
doi: 10.3389/fimmu.2019.00917
In the original article, reference “37” was incorrectly written as “Millrud CR, Bergenfelz C,
Leandersson K. On the origin of myeloid-derived suppressor cells. Oncotarget. (2017) 8:3649–
65. doi: 10.18632/oncotarget.12278” It should be “Ribechini E, Hutchinson JA, Hergovits
S, Heuer M, Lucas J, Schleicher U, et al. Novel GM-CSF signals via IFN-γR/IRF-1
and AKT/mTOR license monocytes for suppressor function. Blood Adv. (2017) 1:947–60.
doi: 10.1182/bloodadvances.2017006858.”
In the original article “Ribechini et al. 2017” was not cited in the article. The citation has now
been inserted in the sectionMediators of MDSC expansion and activation in TB, paragraph one,
and should read:
“Expansion and activation of MDSC is mediated by chronic, low-grade inflammation, resulting
in the pathological activation of myeloid cells (37). Currently, it is difficult to discriminate signals
mediating MDSC expansion from those mediating MDSC activation. Recent findings support a
two-step process involving cellular expansion, licensing, and activation (37, 38). First, chronic
exposure to GM-CSF, IL-6, prostaglandins, and alarmins such as S100A8/9 (38, 39) promote
“emergency myelopoiesis,” impede on terminal maturation of myeloid progenitors. The second
phase involves activation of these “licensed” myeloid cells, through the panoply of inflammatory
cytokines (e.g., IFN-γ, IL-1β, IL- 6, TNF-α, IL-4), DAMPs (e.g., HMGB1), and likely also PAMPs
(e.g., LPS) to obtain suppressive functions (37–39). Such factors are produced during TB and
enriched in TB-susceptible mice accumulating MDSC (Figure 1A) (29). Additional molecules
detected in TB lesions, including prokineticin 2 (PROK 2) and MMP9, which promote MDSC
accumulation in target organs, may also regulate MDSC expansion (29). Recent reports indicate
that transmembrane TNF-alpha regulates the activation and expansion of PMN-MDSC and
M-MDSC in the pleural cavity of BCG infected mice (40). In mycobacterial infections, M-MDSC
are induced regardless of key virulence factors, as M.tb, M.smeg, and BCG have proven to induce
MDSC (13). Consequently, due their immunosuppressive activity and high frequency during
disease progression, MDSC have been identified as one of the factors that may contribute to
a low BCG vaccine efficacy (41). Other factors may include geographical location, helminthic
co-infection, route of BCG administration andmycobacterial strain (42). It is important to note that
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the robust cytokine response often observed following BCG
vaccination, contradicts the MDSC functions described above.
We suspect that this perceived discrepancy, could be ascribed to
the requirement of a 2nd activation signal or the mycobacterial
strain-specific differences on MDSC function. Alternatively,
the MDSC suppressive function might stretch beyond T-cell
immunity and affect other cell subsets which are rarely evaluated
following BCG vaccination, with the route of the vaccination and
the age of the vaccine, also contributing to the outcome. The role
of live bacteria in regions from which MDSC originate, such as
immature bone marrow cells, still need to be investigated.”
The authors apologize for this error and state that this does
not change the scientific conclusions of the article in any way.
The original article has been updated.
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